骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer
產(chǎn)品名稱: 骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer
產(chǎn)品型號: C02-120-10D-100ug
產(chǎn)品展商: peprotech
產(chǎn)品文檔: 無相關(guān)文檔
簡單介紹
骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer系列產(chǎn)品主要適用于試驗(yàn)室或生化科研相關(guān)試驗(yàn),CANSPEC品質(zhì)提供的骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer性能**,中文名稱為骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer。
骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer
的詳細(xì)介紹
產(chǎn)品名稱:骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer
產(chǎn)品規(guī)格:
C02-120-10D-100ug | 骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer | 100ug | ¥12,250 |
C02-120-10D-1mg | 骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer | 1mg | ¥54,600 |
C02-120-10D-20ug | 骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer | 20ug | ¥1,960 |
C02-120-10D-500ug | 骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer | 500ug | ¥32,760 |
C02-120-10D-5ug | 骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer | 5ug | ¥680 |
單 位:瓶
關(guān) 鍵 字:骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer
CANSPEC品質(zhì)提供的骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer性能**,英文名稱骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer,簡稱為骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer,中文名稱為骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer。
產(chǎn)品骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer以其優(yōu)良的品質(zhì)滿足您不同實(shí)驗(yàn)的多種需求。并保證每批 的質(zhì)量和骨形態(tài)生成蛋白-4(BMP-4)拮抗劑Noggin二聚體|Human NOGGIN-Dimer品質(zhì)優(yōu)良。
English Information
Synonyms : | none. |
Description : | Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-β family and regulate their activity by inhibiting their access to signaling receptors. The interplay between TGF-β ligands and their natural antagonists has major biological significance during development processes, in which cellular response can vary considerably depending upon the local concentration of the signaling molecule. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis. Recombinant human Noggin is a 46.2 kDa disulfide-linked homodimer (120-10D) consisting of two 206 amino acid polypeptide chains. |
Catalog #: | 120-10D |
Source : | E.coli |
Stability : | The lyophilized protein is stable for at least 2 years from date of receipt at -200C. Reconstituted Noggin is stable for at least 3 months when stored in working aliquots with a carrier protein at -200C. Avoid repeated freeze/thaw cycles. |
Purity : | Greater than 95% by SDS-PAGE gel and HPLC analyses. |
Endotoxin Level : | Endotoxin level is less than 0.1 ng per μg (1EU/μg). |
Biological Activity : | Determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC chondrogenic cells. The expected The ED50 for this effect is 0.01-0.02 μg/ml of Noggin. |
AA Sequence : | MQHYLHIRPA PSDNLPLVDL IEHPDPIFDP KEKDLNETLL RSLLGGHYDP GFMATSPPED RPGGGGGAAG GAEDLAELDQ LLRQRPSGAM PSEIKGLEFS EGLAQGKKQR LSKKLRRKLQ MWLWSQTFCP VLYAWNDLGS RFWPRYVKVG SCFSKRSCSV PEGMVCKPSK SVHLTVLRWR CQRRGGQRCG WIPIQYPIIS ECKCSC |
PubMed Link : | Noggin |
Country of Origin : | USA |
|